Metformin Shows Promise in Slowing Age-Related Macular Degeneration Progression
核心洞察
University of Liverpool researchers found that diabetic patients over 55 taking metformin were 37% less likely to develop intermediate age-related macular degeneration (搜索) over five years compared to those not taking the drug.
The study analyzed retinal photographs from 2,545 people in Liverpool's diabetic eye screening program, representing the first research to grade AMD (搜索) severity directly from eye images rather than relying on diagnostic codes.
With no current treatment available for geographic atrophy (搜索) and expensive injection therapies for wet AMD (搜索), metformin could offer an accessible treatment option for a condition affecting 1.1-1.8 million people in the UK.
Researchers at the University of Liverpool have discovered that metformin, a widely prescribed diabetes (搜索) medication costing just 35p per pill, may help protect against age-related macular degeneration (搜索) (AMD (搜索)), the leading cause of blindness in high-income countries. The study, published in the BMJ, found that diabetic patients over 55 taking metformin were 37% less likely to develop intermediate AMD over a five-year period compared to those not taking the medication.
Study Design and Methodology
The research team analyzed retinal photographs from 2,545 people who participated in Liverpool's routine diabetic eye disease screening program between 2011 and 2016. Each patient had retinal photographs taken at both time points, which were graded by eye specialists using a recognized classification system for Early AMD (搜索), Intermediate AMD, and Late AMD stages.
Using GP records to identify which patients were prescribed metformin, researchers compared AMD (搜索) development and progression rates between those taking the drug and those who were not. The analysis adjusted for potential confounding factors including age, sex, and duration of diabetes (搜索).
Key Findings
The study revealed that the odds of developing intermediate AMD (搜索) over five years in the metformin group was 0.63 compared to the no metformin group (95% confidence range 0.43 to 0.92). However, metformin did not reduce the chance of developing early AMD or slow progression from early AMD to more advanced stages.
Dr. Nick Beare, the eye doctor who led the research, emphasized the significance of these findings: "Most people who suffer from AMD (搜索) have no treatment, so this is a great breakthrough in our search for new treatments. What we need to do now is test metformin as a treatment for AMD in a clinical trial. Metformin has the potential to save many people's sight."
Clinical Context and Unmet Need
AMD (搜索) affects the central retina (搜索) or macula (搜索) at the back of the eye, eventually causing light-sensitive tissue to die off (geographic atrophy (搜索), a form of 'dry' AMD) or be damaged by abnormal blood vessel growth ('wet' AMD). Intermediate and advanced AMD affects 10-15% of people over 65 years of age, equating to 1.1 to 1.8 million people in the UK.
The condition represents a significant healthcare burden, with an estimated annual cost of £11.1 billion in the UK. Currently, geographic atrophy (搜索) has no treatment available in the UK and Europe, while treatments for wet AMD (搜索) require expensive and unpleasant repeated injections into the eye.
Study Limitations and Future Directions
The researchers acknowledged several limitations in their study. The metformin group was slightly younger and healthier in some ways, and there was limited information about exact metformin dosages and duration of treatment. Additionally, the study lacked data on participants' diets or vitamin supplement use, and the results only apply to people with diabetes (搜索), not the general population.
The research team theorized that metformin might help protect the retina (搜索) through its anti-aging and anti-inflammatory effects, warranting further investigation through dedicated clinical trials.
Broader Implications
This study represents the first research to grade AMD (搜索) severity directly from eye photographs, providing more accurate assessment compared to previous studies that relied on GP diagnostic codes or insurance claims. The findings add to growing evidence of metformin's versatility beyond diabetes (搜索) management, with recent studies also showing the drug's potential in preventing acute myeloid leukemia (搜索).
With AMD (搜索) affecting an estimated 600,000 people in the UK and representing the most common cause of blindness in high-income countries, the potential for repurposing an existing, affordable medication could offer significant clinical and economic benefits if confirmed in future trials.